Circio partners with 4basebio for next-gen synthetic DNA tech

21 January 2025

Oslo, Norway-based biotech Circio (OSE: CRNA) has entered into a partnership with UK-based 4basebio (AIM: 4BB) to develop and test synthetic “circVec” DNA vectors.

The project targets in vivo delivery, whereby gene therapy is introduced into specific cells or tissues within the body to address genetic disorders.

Circio’s proprietary circVec platform has demonstrated up to 70 times prolonged RNA half-life and a 15-fold increase in protein levels compared to standard mRNA-based expression in this context.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology